Myriad Genetics to Present at Multiple Upcoming Healthcare Conferences
February 13 2019 - 4:05PM
Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular
diagnostics and personalized medicine, announced that it will be
presenting at multiple upcoming healthcare conferences.
R. Bryan Riggsbee, chief financial officer at Myriad Genetics
will present at the Leerink Global Healthcare Conference in New
York City on February 27, 2019 at 9:30 am ET. Mr. Riggsbee will
also be attending the BTIG Snowbird Investor Conference on February
28, 2019.Mark C. Capone, president and CEO, is scheduled to present
at 39th annual Cowen Healthcare Conference in Boston, Massachusetts
at 9:20 a.m. ET on March 12, 2019.The presentations will be
available to interested parties through a live audio webcast
accessible through a link in the investor information section of
Myriad’s website at www.myriad.com.
About Myriad GeneticsMyriad Genetics Inc., is a
leading personalized medicine company dedicated to being a trusted
advisor transforming patient lives worldwide with pioneering
molecular diagnostics. Myriad discovers and commercializes
molecular diagnostic tests that: determine the risk of developing
disease, accurately diagnose disease, assess the risk of disease
progression, and guide treatment decisions across six major medical
specialties where molecular diagnostics can significantly improve
patient care and lower healthcare costs. Myriad is focused on
five strategic imperatives: build upon a solid hereditary
cancer foundation, growing new product volume, expanding
reimbursement coverage for new products, increasing RNA kit revenue
internationally and improving profitability with Elevate
2020. For more information on how Myriad is making a
difference, please visit the Company's website:
www.myriad.com.Myriad, the Myriad logo, BART, BRACAnalysis,
Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk
Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor
BRACAnalysis CDx, myChoice HRD, EndoPredict, Vectra, GeneSight,
riskScore, Prequel, Foresight and Prolaris are trademarks or
registered trademarks of Myriad Genetics, Inc. or its wholly owned
subsidiaries in the United States and foreign countries. MYGN-F,
MYGN-G.
Media Contact:
|
Ron Rogers |
Investor Contact: |
Scott Gleason |
|
(801)
584-3065 |
|
(801) 584-1143 |
|
rrogers@myriad.com |
|
sgleason@myriad.com |
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Apr 2023 to Apr 2024